Treatment of Neuroblastoma with an Engineered “Obligate” Anaerobic Salmonella typhimurium Strain YB1.
J Cancer 2017; 8(9):1609-1618. doi:10.7150/jca.18776. * equal contribution
Angiogenic inhibitors delivered by the type III secretion system of tumor-targeting Salmonella typhimurium safely shrink tumors in mice.
AMB Expr (2016) 6: 56. doi:10.1186/s13568-016-0226-8
An “obligate” anaerobic Salmonella strain YB1 suppresses liver tumor growth and metastasis in nude mice.
Oncol Lett. 2016 Nov:177-183
Combined prokaryotic-eukaryotic delivery and expression of therapeutic factors through a primed autocatalytic positive-feedback loop.
Journal of Controlled Release 2016 Jan 28;222:130-40.
Obligate anaerobic Salmonella typhimurium strain YB1 treatment on xenograft tumor in immunocompetent mouse model.
Oncol Lett. 2015 Aug; 10(2): 1069–1074.
Genetically modified "obligate" anaerobic Salmonella typhimurium as a therapeutic strategy for neuroblastoma.
J Hematol Oncol. 2015 Aug 19;8:99. doi: 10.1186/s13045-015-0196-3.
Comparative immunological evaluation of recombinant Salmonella Typhimurium strains expressing model antigens as live oral vaccines.
equal contribution. BMC Immunology 2012, 13:54
Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella Typhimurium strain.
equal contribution. Scientific Reports. 2012, 2:436
A method to generate recombinant Salmonella typhi Ty21a strains expressing multiple heterologous genes using an improved recombineering strategy.
Appl Microbiol Biotechnol. 2011, 91(1): 177-188
